Abstract
MeCP2 is a fundamental protein associated with several neurological disorders, including Rett syndrome. It is considered a multifunctional factor with a prominent role in regulating chromatin structure; however, a full comprehension of the consequences of its deficiency is still lacking. Here, we characterize a novel mouse model of Mecp2 bearing the human mutation Y120D, which is localized in the methyl-binding domain. As most models of Mecp2, the Mecp2Y120D mouse develops a severe Rett-like phenotype. This mutation alters the interaction of the protein with chromatin, but surprisingly, it also impairs its association with corepressors independently on the involved interacting domains. These features, which become overt mainly in the mature brain, cause a more accessible and transcriptionally active chromatin structure; conversely, in the Mecp2-null brain, we find a less accessible and transcriptionally inactive chromatin. By demonstrating that different MECP2 mutations can produce concordant neurological phenotypes but discordant molecular features, we highlight the importance of considering personalized approaches for the treatment of Rett syndrome.
Similar content being viewed by others
References
Amir RE, Van den Veyver IB, Wan M et al (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23:185–188. https://doi.org/10.1038/13810
Neul JL, Kaufmann WE, Glaze DG et al (2010) Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 68:944–950. https://doi.org/10.1002/ana.22124
Baker SA, Chen L, Wilkins AD, Yu P, Lichtarge O, Zoghbi HY (2013) An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders. Cell 152:984–996. https://doi.org/10.1016/j.cell.2013.01.038
Bedogni F, Rossi RL, Galli F, Cobolli Gigli C, Gandaglia A, Kilstrup-Nielsen C, Landsberger N (2014) Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action. Neurosci Biobehav Rev 46:187–201. https://doi.org/10.1016/j.neubiorev.2014.01.011
Lyst MJ, Ekiert R, Ebert DH, Merusi C, Nowak J, Selfridge J, Guy J, Kastan NR et al (2013) Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci 16:898–902. https://doi.org/10.1038/nn.3434
Nan X, Hou J, Maclean A, Nasir J, Lafuente MJ, Shu X, Kriaucionis S, Bird A (2007) Interaction between chromatin proteins MECP2 and ATRX is disrupted by mutations that cause inherited mental retardation. Proc Natl Acad Sci 104:2709–2714. https://doi.org/10.1073/pnas.0608056104
Skene PJ, Illingworth RS, Webb S, Kerr ARW, James KD, Turner DJ, Andrews R, Bird AP (2010) Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell 37:457–468. https://doi.org/10.1016/j.molcel.2010.01.030
Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27:327–331. https://doi.org/10.1038/85906
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27:322–326. https://doi.org/10.1038/85899
Ricceri L, De Filippis B, Laviola G (2008) Mouse models of Rett syndrome: from behavioural phenotyping to preclinical evaluation of new therapeutic approaches. Behav Pharmacol 19:501–517. https://doi.org/10.1097/FBP.0b013e32830c3645
Stearns NA, Schaevitz LR, Bowling H, Nag N, Berger UV, Berger-Sweeney J (2007) Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neuroscience 146:907–921. https://doi.org/10.1016/j.neuroscience.2007.02.009
Brown K, Selfridge J, Lagger S, Connelly J, de Sousa D, Kerr A, Webb S, Guy J et al (2016) The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet 25:558–570. https://doi.org/10.1093/hmg/ddv496
Bellini E, Pavesi G, Barbiero I, Bergo A, Chandola C, Nawaz MS, Rusconi L, Stefanelli G et al (2014) MeCP2 post-translational modifications: a mechanism to control its involvement in synaptic plasticity and homeostasis? Front Cell Neurosci 8:236. https://doi.org/10.3389/fncel.2014.00236
Goffin D, Allen M, Zhang L, Amorim M, Wang ITJ, Reyes ARS, Mercado-Berton A, Ong C et al (2012) Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci 15:274–283. https://doi.org/10.1038/nn.2997
D’Annessa I, Gandaglia A, Brivio E et al (2018) Tyr120Asp mutation alters domain flexibility and dynamics of MeCP2 DNA binding domain leading to impaired DNA interaction: atomistic characterization of a Rett syndrome causing mutation. Biochim Biophys Acta Gen Subj 1862:1180–1189. https://doi.org/10.1016/j.bbagen.2018.02.005
Inui K, Akagi M, Ono J, Tsukamoto H, Shimono K, Mano T, Imai K, Yamada M et al (2001) Mutational analysis of MECP2 in Japanese patients with atypical Rett syndrome. Brain and Development 23:212–215. https://doi.org/10.1016/S0387-7604(01)00197-8
Agarwal N, Becker A, Jost KL, Haase S, Thakur BK, Brero A, Hardt T, Kudo S et al (2011) MeCP2 Rett mutations affect large scale chromatin organization. Hum Mol Genet 20:4187–4195. https://doi.org/10.1093/hmg/ddr346
Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Schanen C, Tamura M (2003) Heterogeneity in residual function of MeCP2 carrying missense mutations in the methyl CpG binding domain. J Med Genet 40:487–493. https://doi.org/10.1136/jmg.40.7.487
Stefanelli G, Gandaglia A, Costa M, Cheema MS, di Marino D, Barbiero I, Kilstrup-Nielsen C, Ausió J et al (2016) Brain phosphorylation of MeCP2 at serine 164 is developmentally regulated and globally alters its chromatin association. Sci Rep 6:28295. https://doi.org/10.1038/srep28295
Bergo A, Strollo M, Gai M et al (2015) Methyl-CpG binding protein 2 (MeCP2) localizes at the centrosome and is required for proper mitotic spindle organization. J Biol Chem 290:3223–3237. https://doi.org/10.1074/jbc.M114.608125
Cobolli Gigli C, Scaramuzza L, Gandaglia A, Bellini E, Gabaglio M, Parolaro D, Kilstrup-Nielsen C, Landsberger N et al (2016) MeCP2 related studies benefit from the use of CD1 as genetic background. PLoS One 11:e0153473. https://doi.org/10.1371/journal.pone.0153473
Guy J, Gan J, Selfridge J, Cobb S, Bird A (2007) Reversal of neurological defects in a mouse model of Rett syndrome. Science 315:1143–1147. https://doi.org/10.1126/science.1138389
Antonucci F, Corradini I, Morini R, Fossati G, Menna E, Pozzi D, Pacioni S, Verderio C et al (2013) Reduced SNAP-25 alters short-term plasticity at developing glutamatergic synapses. EMBO Rep 14:645–651. https://doi.org/10.1038/embor.2013.75
Shahbazian MD, Young JI, Yuva-Paylor LA, Spencer CM, Antalffy BA, Noebels JL, Armstrong DL, Paylor R et al (2002) Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron 35:243–254. https://doi.org/10.1016/S0896-6273(02)00768-7
Katz DM, Berger-Sweeney JE, Eubanks JH, Justice MJ, Neul JL, Pozzo-Miller L, Blue ME, Christian D et al (2012) Preclinical research in Rett syndrome: setting the foundation for translational success. Dis Model Mech 5:733–745. https://doi.org/10.1242/dmm.011007
Bedogni F, Cobolli Gigli C, Pozzi D, Rossi RL, Scaramuzza L, Rossetti G, Pagani M, Kilstrup-Nielsen C et al (2016) Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb Cortex 26:2517–2529. https://doi.org/10.1093/cercor/bhv078
Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lovén J, Kwok SM, Feldman DA et al (2013) Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13:446–458. https://doi.org/10.1016/j.stem.2013.09.001
Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, Calcagno E, Morello N et al (2011) Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 20:1182–1196. https://doi.org/10.1093/hmg/ddq563
Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, Greer JJ, Zoghbi HY et al (2008) A partial loss of function allele of methyl-CpG-binding protein 2 predicts a human neurodevelopmental syndrome. Hum Mol Genet 17:1718–1727. https://doi.org/10.1093/hmg/ddn062
Guy J, Cheval H, Selfridge J, Bird A (2011) The role of MeCP2 in the brain. Annu Rev Cell Dev Biol 27:631–652. https://doi.org/10.1146/annurev-cellbio-092910-154121
Kruusvee V, Lyst MJ, Taylor C, Tarnauskaitė Ž, Bird AP, Cook AG (2017) Structure of the MeCP2–TBLR1 complex reveals a molecular basis for Rett syndrome and related disorders. Proc Natl Acad Sci 114:E3243–E3250. https://doi.org/10.1073/pnas.1700731114
Egloff S, Murphy S (2008) Role of the C-terminal domain of RNA polymerase II in expression of small nuclear RNA genes. Biochem Soc Trans 36:537–539. https://doi.org/10.1042/BST0360537
Hirose Y, Ohkuma Y (2007) Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem 141:601–608. https://doi.org/10.1093/jb/mvm090
Linhoff MW, Garg SK, Mandel G (2015) A high-resolution imaging approach to investigate chromatin architecture in complex tissues. Cell 163:246–255. https://doi.org/10.1016/j.cell.2015.09.002
Phatnani HP, Greenleaf AL (2006) Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 20:2922–2936. https://doi.org/10.1101/gad.1477006
Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y et al (2013) Global epigenomic reconfiguration during mammalian brain development. Science 1237905–1237905:341. https://doi.org/10.1126/science.1237905
Ludwig AK, Zhang P, Hastert FD, Meyer S, Rausch C, Herce HD, Müller U, Lehmkuhl A et al (2017) Binding of MBD proteins to DNA blocks Tet1 function thereby modulating transcriptional noise. Nucleic Acids Res 45:2438–2457. https://doi.org/10.1093/nar/gkw1197
Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N (2012) MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151:1417–1430. https://doi.org/10.1016/j.cell.2012.11.022
Lamonica JM, Kwon DY, Goffin D, Fenik P, Johnson BS, Cui Y, Guo H, Veasey S et al (2017) Elevating expression of MeCP2 T158M rescues DNA binding and Rett syndrome–like phenotypes. J Clin Invest 127:1889–1904. https://doi.org/10.1172/JCI90967
Thambirajah AA, Eubanks JH, Ausió J (2009) MeCP2 post-translational regulation through PEST domains: two novel hypotheses. BioEssays 31:561–569. https://doi.org/10.1002/bies.200800220
Riedmann C, Fondufe-Mittendorf YN (2016) Comparative analysis of linker histone H1, MeCP2, and HMGD1 on nucleosome stability and target site accessibility. Sci Rep 6:33186. https://doi.org/10.1038/srep33186
Tillotson R, Selfridge J, Koerner MV, Gadalla KKE, Guy J, de Sousa D, Hector RD, Cobb SR et al (2017) Radically truncated MeCP2 rescues Rett syndrome-like neurological defects. Nature 550:398–401. https://doi.org/10.1038/nature24058
Acknowledgments
We are extremely grateful to Giovanni Tonon and Simona Segalla (San Raffaele Scientific Institute) for their helpful technical suggestions. Part of this work was carried out in ALEMBIC, an advanced microscopy laboratory established by IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele.
Funding
This work was mainly supported by the Italian parents’ association “pro RETT ricerca” to N.L. Financial support was from Fondazione Telethon, Italy (Grant no. GGP16015 to F.A.). Functional experiments were supported by the Italian Ministry of Research and Education program “FIRB giovani” 2010, protocol number RBFR10ZBYZ. Fondazione Veronesi (Milan, Italy) provided additional funding to F.B.
Author information
Authors and Affiliations
Contributions
A.G and N. L conceptualized and designed most of the study. P.D-A and F.A. assisted the design and realization of the behavioral and electrophysiological studies, respectively. A.G., E.B., A.B., B.L., C.C., S.C., G.S., L.P., V.B., F.B., M.P., and M.C. conducted the experiments, prepared most of the figures, and revised the manuscript. A.F. helped with statistical analysis of data. N.L. wrote the manuscript with the assistance of A.F. D.D-M, I.D., and C.K-N assisted in interpreting and discussing results.
Corresponding author
Ethics declarations
Research involving animals was performed in accordance with the European Community Council Directive 2010/63/UE for care and use of experimental animals; all the protocols were approved by the Italian Minister for Scientific Research and by the San Raffaele Scientific Institutional Animal Care and Use Committee in accordance with the Italian law.
Conflict of Interest
The authors declare that they have no conflict of interest.
Electronic Supplementary Material
ESM 1
(PDF 570 KB)
Rights and permissions
About this article
Cite this article
Gandaglia, A., Brivio, E., Carli, S. et al. A Novel Mecp2Y120D Knock-in Model Displays Similar Behavioral Traits But Distinct Molecular Features Compared to the Mecp2-Null Mouse Implying Precision Medicine for the Treatment of Rett Syndrome. Mol Neurobiol 56, 4838–4854 (2019). https://doi.org/10.1007/s12035-018-1412-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-018-1412-2